DCT

2:24-cv-09691

Teva Branded Pharmaceutical Products R&D Inc v. Cipla USA Inc

Log In

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 2:24-cv-09691, D.N.J., 10/09/2024
  • Venue Allegations: Venue is asserted based on Defendant Cipla USA, Inc. having its principal place of business in New Jersey and Defendant Cipla Ltd. being subject to personal jurisdiction within the district.
  • Core Dispute: Plaintiffs allege that Defendants' Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Plaintiffs' QVAR RediHaler® product infringes sixteen patents related to metered-dose inhaler devices and methods of use.
  • Technical Context: The dispute centers on the technology of metered-dose inhalers, specifically devices for the maintenance treatment of asthma, which represent a significant segment of the pharmaceutical market.
  • Key Procedural History: The complaint indicates a history of litigation between the parties, referencing prior lawsuits filed by Teva against Cipla in 2024 concerning a 40 mcg version of the accused product. This action, concerning an 80 mcg version, was initiated after Cipla sent a Paragraph IV Notice Letter to Teva on September 12, 2024, asserting that the patents-in-suit are invalid or would not be infringed. The complaint also alleges a pre-suit dispute over the terms of Cipla's Offer of Confidential Access (OCA) to its ANDA materials.

Case Timeline

Date Event
2007-04-11 ’712 Patent Priority Date
2009-06-18 ’476 Patent Priority Date
2010-05-18 Priority Date for ’509, ’510, ’156, ’808, ’512, ’889 Patents
2012-03-13 ’712 Patent Issued
2015-01-13 ’476 Patent Issued
2017-02-14 Priority Date for ’888, ’637, ’643, ’953, ’247, ’759 Patents
2018-01-26 Priority Date for ’447, ’832 Patents
2018-07-17 ’509 and ’510 Patents Issued
2018-10-02 ’156 Patent Issued
2020-02-18 ’808 Patent Issued
2020-06-30 ’512 Patent Issued
2020-10-06 ’447 Patent Issued
2022-07-26 ’888 and ’889 Patents Issued
2023-01-24 ’637 Patent Issued
2023-02-21 ’643 Patent Issued
2023-10-24 ’953 Patent Issued
2024-01-04 Cipla's First 40 mcg Notice Letter
2024-01-09 ’247 Patent Issued
2024-02-13 ’759 Patent Issued
2024-02-16 Teva files first lawsuit regarding 40 mcg ANDA
2024-03-15 Cipla's Second 40 mcg Notice Letter
2024-04-16 ’832 Patent Issued
2024-04-23 Cipla's Third 40 mcg Notice Letter
2024-05-06 Teva files second lawsuit regarding 40 mcg ANDA
2024-05-31 Cipla's Fourth 40 mcg Notice Letter
2024-06-21 Teva files third lawsuit regarding 40 mcg ANDA
2024-09-12 Cipla's 80 mcg Notice Letter (re: Patents-in-Suit)
2024-10-09 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,132,712 - "Metered-Dose Inhaler"

  • Patent Identification: U.S. Patent No. 8,132,712, "Metered-Dose Inhaler," issued March 13, 2012 (Compl. ¶26).

The Invention Explained

  • Problem Addressed: The patent describes a drawback of self-administered inhalers wherein it is difficult for a user to determine the amount of active drug remaining in the device, which can lead to unreliable dosing (U.S. Patent No. 8,132,712, col. 1:44-53). Conventional dose counters could be unreliable, particularly if subjected to physical shock.
  • The Patented Solution: The invention is a dose counter mechanism for a metered-dose inhaler that aims to prevent miscounting. The core of the solution is a "pawl" (a mechanism that engages a gear) designed with "at least two ratchet teeth" that are "radially spaced." This configuration is intended to ensure that after each step-wise turn of the counter's rotary gear, one of the pawl's teeth reliably engages the gear wheel to prevent reverse rotation and ensure accurate counting ('712 Patent, col. 2:48-56, Abstract).
  • Technical Importance: The invention addresses the need for highly reliable dose counters to enhance patient safety and ensure proper administration of medication from manually operated inhalers.

Key Claims at a Glance

  • The complaint asserts independent claims 1, 18, and 19 (Compl. ¶144).
  • The essential elements of independent claim 1, a device claim, are:
    • A dose counter for a metered-dose inhaler, comprising: an actuator, a rotary gear, and a driver for moving the gear.
    • The rotary gear is a wheel with ratchet teeth on its periphery.
    • A pawl is included to prevent reverse rotation of the gear.
    • A display is coupled to the gear to show the dose count.
    • The inventive step requires that the pawl itself comprises at least two ratchet teeth.
    • These two teeth on the pawl are radially spaced to ensure one of them engages the wheel's teeth after each step of rotary motion (Compl. ¶29).

U.S. Patent No. 8,931,476 - "Inhaler"

  • Patent Identification: U.S. Patent No. 8,931,476, "Inhaler," issued January 13, 2015 (Compl. ¶32).

The Invention Explained

  • Problem Addressed: The patent background explains that air inlets on inhalers, particularly breath-actuated devices, can be accidentally covered or occluded by the patient's hand or finger during use, which can prevent or adversely influence the airflow and cause the device to malfunction (U.S. Patent No. 8,931,476, col. 1:7-17).
  • The Patented Solution: The invention is a specific geometric design for the air inlet means of an inhaler. It comprises an array of apertures where the opening for each aperture "extends in two different planes." If a patient's finger covers one plane of the opening, this design creates a "void space" between the finger and the aperture, allowing air to continue flowing through the uncovered portion of the opening in the second plane, thus ensuring the required airflow is maintained ('476 Patent, Abstract; col. 2:38-49).
  • Technical Importance: This design provides a more robust and reliable airflow path for an inhaler, reducing the risk of malfunction due to accidental blockage by the user.

Key Claims at a Glance

  • The complaint asserts independent claims 1 and 17 (Compl. ¶154).
  • The essential elements of independent claim 1 are:
    • An inhaler with a housing that defines an air flow path.
    • The air inlet comprises an array of elongate apertures.
    • The opening of each aperture extends in "two different planes."
    • This geometry creates a "void space" if a part of the opening is covered, providing an alternative air flow path.
    • A "raised formation" is provided between adjacent apertures to limit or prevent a covered opening (Compl. ¶35).

U.S. Patent No. 10,022,509 - "Dose Counter for Inhaler Having a Bore and Shaft Arrangement"

  • Patent Identification: U.S. Patent No. 10,022,509, "Dose Counter for Inhaler Having a Bore and Shaft Arrangement," issued July 17, 2018 (Compl. ¶37).
  • Technology Synopsis: This patent describes a dose counter mechanism that uses a display tape driven from a stock bobbin. The invention focuses on the interaction between the bobbin's internal bore and its support shaft, where a radially extending protrusion on one part creates resilient frictional engagement with the other to regulate the tape's movement and prevent unwanted unwinding (Compl. ¶40; '509 Patent, col. 1:45-51).
  • Asserted Claims: Claim 1 (Compl. ¶164).
  • Accused Features: The complaint alleges on information and belief that Cipla's ANDA Product includes a dose counter that infringes this patent (Compl. ¶164).

U.S. Patent No. 10,022,510 - "Dose Counters for Inhalers, Inhalers and Methods of Assembly Thereof"

  • Patent Identification: U.S. Patent No. 10,022,510, "Dose Counters for Inhalers, Inhalers and Methods of Assembly Thereof," issued July 17, 2018 (Compl. ¶41).
  • Technology Synopsis: This patent covers an inhaler with a dose counter tape system that includes specific indicia. A key feature is "priming indicia" located on the tape and visible in the viewing window before the inhaler's first use, distinguishing it from the regular dosing numbers (Compl. ¶44, ¶45, ¶46).
  • Asserted Claims: Claims 1, 10, and 20 (Compl. ¶174).
  • Accused Features: The complaint alleges on information and belief that the dose counter in Cipla's ANDA Product will have a tape system with indicia that infringe these claims (Compl. ¶174).

U.S. Patent No. 10,086,156 - "Dose Counter for Inhaler and Method of Counting Doses"

  • Patent Identification: U.S. Patent No. 10,086,156, "Dose Counter for Inhaler and Method of Counting Doses," issued October 2, 2018 (Compl. ¶47).
  • Technology Synopsis: This patent describes a dose counter that ensures the medicament is fired before the dose counter registers the count. It claims a specific sequence of actuator positions (reset, fire, count) and a specific spatial relationship where the actuator pawl is below a "datum plane" during the "canister fire configuration" (Compl. ¶50). This addresses the technical problem of ensuring a count is only registered after a dose has been successfully delivered.
  • Asserted Claims: Claim 1 (Compl. ¶184).
  • Accused Features: The complaint alleges on information and belief that the dose counter in Cipla's ANDA Product will operate according to the claimed sequence (Compl. ¶184).

U.S. Patent No. 10,561,808 - "Dose Counter for Inhaler Having an Anti-Reverse Rotation Actuator"

  • Patent Identification: U.S. Patent No. 10,561,808, "Dose Counter for Inhaler Having an Anti-Reverse Rotation Actuator," issued February 18, 2020 (Compl. ¶51).
  • Technology Synopsis: This patent relates to a dose counter with a drive system that moves a counter display incrementally. The invention is a "regulator" at a "first station" (before the display window) that acts on the counter display to "regulate motion... to incremental movements," which helps prevent unwanted motion if the counter is dropped ('808 Patent, col. 1:45-58; Compl. ¶54).
  • Asserted Claims: Claim 1 (Compl. ¶194).
  • Accused Features: The complaint alleges on information and belief that the dose counter in Cipla's ANDA Product will contain a regulator mechanism that infringes this claim (Compl. ¶194).

U.S. Patent No. 10,695,512 - "Dose Counter for Inhaler Having an Anti-Reverse Rotation Actuator"

  • Patent Identification: U.S. Patent No. 10,695,512, "Dose Counter for Inhaler Having an Anti-Reverse Rotation Actuator," issued June 30, 2020 (Compl. ¶55).
  • Technology Synopsis: This patent describes a method for mounting a dose counter chassis onto the main body of an inhaler. The invention involves using a plurality of apertures and pins on the body and chassis for alignment and stabilization, with at least one pin or aperture being "heat staked" to permanently mount the chassis to the body (Compl. ¶58).
  • Asserted Claims: Claim 1 (Compl. ¶204).
  • Accused Features: The complaint alleges on information and belief that Cipla's ANDA Product will be assembled using a heat-staking method that infringes this claim (Compl. ¶204).

U.S. Patent No. 10,792,447 - "Breath Actuated Inhaler"

  • Patent Identification: U.S. Patent No. 10,792,447, "Breath Actuated Inhaler," issued October 6, 2020 (Compl. ¶59).
  • Technology Synopsis: This patent covers a breath-actuated inhaler with a "pneumatic force holding unit." This unit retains the canister actuation force via a pressure difference. The key claimed feature is the stability of this force, which reduces by "less than about 6% over a period of 5 minutes" when in the prepared configuration (Compl. ¶62, ¶63).
  • Asserted Claims: Claims 1 and 10 (Compl. ¶214).
  • Accused Features: The complaint alleges on information and belief that the breath-actuation mechanism in Cipla's ANDA Product will have a pneumatic force holding unit that meets this specific force reduction limitation (Compl. ¶214).

U.S. Patent No. 11,395,888 - "Inhalers and Related Methods"

  • Patent Identification: U.S. Patent No. 11,395,888, "Inhalers and Related Methods," issued July 26, 2022 (Compl. ¶64).
  • Technology Synopsis: This patent pertains to a breath-actuated inhaler with specific operational parameters. It claims a drive adapted to apply a firing force between 35 N and 60 N, a pressurized canister adapted to move between 1 and 4 mm, and a "ready-to-fire configuration" where a vacuum force combines with spring forces to oppose the drive force (Compl. ¶67, ¶68).
  • Asserted Claims: Claims 1 and 25 (Compl. ¶224).
  • Accused Features: The complaint alleges on information and belief that the drive mechanism in Cipla's ANDA Product will meet the claimed force and travel distance parameters (Compl. ¶224).

U.S. Patent No. 11,395,889 - "Dose Counter for Inhaler Having an Anti-Reverse Rotation Actuator"

  • Patent Identification: U.S. Patent No. 11,395,889, "Dose Counter for Inhaler Having an Anti-Reverse Rotation Actuator," issued July 26, 2022 (Compl. ¶69).
  • Technology Synopsis: This patent describes an incremental dose counter where the actuator itself acts as an "anti-back drive member" to restrict reverse motion of the output member when the actuator is in a non-depressed position. It further claims a "second anti-back member" that restricts reverse motion when the actuator is disengaged (Compl. ¶72).
  • Asserted Claims: Claim 1 (Compl. ¶234).
  • Accused Features: The complaint alleges on information and belief that the dose counter in Cipla's ANDA Product will contain a dual anti-back drive system that infringes this claim (Compl. ¶234).

U.S. Patent No. 11,559,637 - "Inhalers and Related Methods"

  • Patent Identification: U.S. Patent No. 11,559,637, "Inhalers and Related Methods," issued January 24, 2023 (Compl. ¶73).
  • Technology Synopsis: This patent claims a breath-actuated inhaler having a specific "lock system" to attach the cap housing to the main body. The system uses helical threads with "non-overlapping and distinct thread segments" and a cooperating lock member to create a "snap lock" in the locked position (Compl. ¶76, ¶77).
  • Asserted Claims: Claims 1 and 28 (Compl. ¶244).
  • Accused Features: The complaint alleges on information and belief that the assembly of Cipla's ANDA Product will use a locking system that infringes these claims (Compl. ¶244).

U.S. Patent No. 11,583,643 - "Inhalers and Related Methods"

  • Patent Identification: U.S. Patent No. 11,583,643, "Inhalers and Related Methods," issued February 21, 2023 (Compl. ¶78).
  • Technology Synopsis: This patent claims a method of metering inhalable substances to prevent gas from becoming trapped in the metering chamber. The method involves operating the inhaler to allow atmospheric air to enter the chamber for a period (e.g., 2 to 24 hours), then orienting the device so liquid from the reservoir displaces the air before administering a dose (Compl. ¶81, ¶82, ¶83).
  • Asserted Claims: Claims 1, 35, 36, 37, 38, 39, and 40 (Compl. ¶254).
  • Accused Features: The complaint alleges on information and belief that the proposed labeling for Cipla's ANDA Product will instruct users to use the device in a manner that performs the patented method (Compl. ¶256).

U.S. Patent No. 11,793,953 - "Inhalers and Related Methods"

  • Patent Identification: U.S. Patent No. 11,793,953, "Inhalers and Related Methods," issued October 24, 2023 (Compl. ¶88).
  • Technology Synopsis: This patent also claims a method, specifically for "preventing gas lock" in an inhaler. The steps include allowing atmospheric gas into the metering chamber, retracting the valve stem for a period to create a communication path, and then altering the orientation to cause fluid to enter the chamber and displace the gas (Compl. ¶91, ¶92). This is closely related to the technology of the '643 patent.
  • Asserted Claims: Claims 1 and 39 (Compl. ¶264).
  • Accused Features: The complaint alleges on information and belief that the use of Cipla's ANDA Product as directed by its labeling will constitute infringement of this method patent (Compl. ¶266).

U.S. Patent No. 11,865,247 - "Inhalers and Related Methods"

  • Patent Identification: U.S. Patent No. 11,865,247, "Inhalers and Related Methods," issued January 9, 2024 (Compl. ¶93).
  • Technology Synopsis: This patent describes a breath-actuated inhaler where a drive applies variable forces to the canister. In the "ready-to-fire" position, the drive force is in equilibrium with balancing forces from a dose counter biasing element and a vacuum chamber. This claims a specific force-balance relationship that defines the device's prepared state (Compl. ¶96).
  • Asserted Claims: Claim 1 (Compl. ¶274).
  • Accused Features: The complaint alleges on information and belief that the mechanism of Cipla's ANDA Product will operate according to this claimed equilibrium of forces (Compl. ¶274).

U.S. Patent No. 11,896,759 - "Inhalers and Related Methods"

  • Patent Identification: U.S. Patent No. 11,896,759, "Inhalers and Related Methods," issued February 13, 2024 (Compl. ¶97).
  • Technology Synopsis: This patent claims an inhaler with a specific lock system for the cap housing, similar to the '637 patent. The invention also includes a metering valve arranged so that when the reservoir is oriented above the metering chamber, gas in the chamber is replaced with liquid. This combines the locking mechanism with the gas-lock prevention technology (Compl. ¶101).
  • Asserted Claims: Claim 1 (Compl. ¶284).
  • Accused Features: The complaint alleges on information and belief that Cipla's ANDA Product will have a combined locking system and metering valve configuration that infringes this claim (Compl. ¶284).

U.S. Patent No. 11,957,832 - "Breath Actuated Inhaler"

  • Patent Identification: U.S. Patent No. 11,957,832, "Breath Actuated Inhaler," issued April 16, 2024 (Compl. ¶102).
  • Technology Synopsis: This patent claims a "valve port for a pneumatic force holding unit" in a breath-actuated inhaler. The claimed features relate to the micro-geometry of the port, requiring a valve seal surface with a surface roughness average (RA) of less than about 0.15 µm, and an annular boss with specific volumetric or angular dimensions (Compl. ¶105).
  • Asserted Claims: Claim 1 (Compl. ¶294).
  • Accused Features: The complaint alleges on information and belief that the valve port in Cipla's ANDA Product will have the claimed surface roughness and dimensional characteristics (Compl. ¶294).

III. The Accused Instrumentality

Product Identification

  • The accused product is Cipla's generic version of Plaintiffs' QVAR RediHaler® (beclomethasone dipropionate, 80 mcg) product, for which Cipla submitted Abbreviated New Drug Application ("ANDA") No. 219774 to the U.S. Food and Drug Administration (Compl. ¶1). The product is identified as "Cipla's Beclomethasone Dipropionate Inhalation Aerosol, 80 mcg" (Compl. ¶7, ¶134).

Functionality and Market Context

  • The complaint alleges that the product is a generic drug for the maintenance treatment of asthma (Compl. ¶25). As this is an ANDA litigation initiated pre-launch, the complaint does not provide specific details on the functionality of Cipla's product itself. Instead, the allegations are based on the legal premise that by filing an ANDA to obtain approval for a generic version of the branded QVAR RediHaler® product, Cipla is seeking to market a product that is the bioequivalent of and will necessarily have the same or equivalent structural and functional features covered by the patents-in-suit (Compl. ¶1, ¶133). The complaint states that Cipla's notice letter and "Detailed Statement" failed to provide sufficient information for Plaintiffs to evaluate Cipla's assertions of noninfringement (Compl. ¶140).
  • No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint alleges on "information and belief" that the manufacture, use, or sale of Cipla's ANDA Product would infringe at least one claim of each of the sixteen patents-in-suit, either literally or under the doctrine of equivalents (Compl. ¶144, 154, 164, 174, 184, 194, 204, 214, 224, 234, 244, 254, 264, 274, 284, 294). The complaint does not provide a claim chart or any specific factual allegations mapping individual claim elements to the features of the accused product. This pleading style is characteristic of ANDA litigation filed under 35 U.S.C. § 271(e)(2) before the plaintiff has had access to the full details of the generic product's design and manufacturing process.

Identified Points of Contention

  • Technical Questions: The primary technical questions are not yet defined in the complaint. They will arise during discovery as Plaintiffs gain access to Cipla's ANDA and product samples. The disputes will center on whether the specific mechanical designs of Cipla's dose counter, air intake, breath-actuation system, and locking mechanisms are the same as or equivalent to those claimed in the asserted patents. For the method patents ('643 and '953), the dispute will focus on whether the product's design and instructions for use will inevitably lead to the performance of the claimed steps for preventing gas lock.
  • Scope Questions: Given the numerous patents covering various mechanical features, a central issue will be the scope of the claim terms. For example, for the '712 patent, a question may be "What constitutes 'at least two ratchet teeth' on a single pawl?" For the '476 patent, a question may be "Does the geometry of the accused device's air inlets meet the claim requirement of extending in 'two different planes'?" The resolution of these and other claim construction questions will be dispositive for infringement.

V. Key Claim Terms for Construction

  • The Term: "pawl comprises at least two ratchet teeth... radially spaced" (from claim 1 of the '712 Patent).
  • Context and Importance: This phrase appears to be a key point of novelty for the '712 Patent's dose counter, designed to ensure reliable engagement and prevent miscounting. Practitioners may focus on this term because its interpretation will determine whether a variety of anti-reverse rotation mechanisms fall within the claim's scope. The dispute will likely center on the structural definition of "teeth" on the pawl and the functional meaning of "radially spaced."
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification's description of preventing "undesirable backwards rotation" could support construing the term to cover any mechanism on a pawl that provides two distinct, radially offset points of contact to block reverse movement, regardless of its specific shape ('712 Patent, col. 4:35-40).
    • Evidence for a Narrower Interpretation: The figures and description of the preferred embodiment show a pawl with two physically distinct, tooth-shaped projections ('712 Patent, Fig. 5). This could support a narrower construction requiring a structure that a person of ordinary skill would recognize as having two separate "teeth."
  • The Term: "wherein the opening of each aperture extends in two different planes" (from claim 1 of the '476 Patent).
  • Context and Importance: This limitation defines the core of the '476 Patent's solution to prevent accidental blockage of the inhaler's air inlets. The infringement analysis will depend on whether the geometry of the accused product's air inlets can be characterized as extending in two different planes.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification's goal is to create a "void space" to provide an alternate airflow path ('476 Patent, col. 2:44-49). This purpose might support a broad construction that reads on any non-planar or curved opening that achieves this result.
    • Evidence for a Narrower Interpretation: The language "two different planes" suggests a specific geometric arrangement, potentially requiring two distinct, flat surfaces meeting at an angle rather than a continuous curve. The claim's further mention of planes defining "an angle of at least 45 degrees to each other" in dependent claims may be used to argue for a more geometrically precise definition ('476 Patent, col. 11:1-12, Claim 17).

VI. Other Allegations

  • Indirect Infringement: For each of the sixteen asserted patents, the complaint alleges that Cipla plans and intends to actively induce infringement and knows that its ANDA product and proposed labeling are especially made or adapted for infringing use and are not suitable for substantial non-infringing use (Compl. ¶¶ 147-148, 157-158, etc.). The basis for inducement is the allegation that Cipla's proposed product labeling will instruct end-users to use the product in an infringing manner (Compl. ¶146).
  • Willful Infringement: The complaint alleges that Cipla has acted with full knowledge of the patents-in-suit and without a reasonable basis for believing it would not be liable for infringement (Compl. ¶¶ 150, 160, etc.). This allegation of pre-suit knowledge is based on Cipla's awareness of the patents via their listing in the FDA's Orange Book and Cipla's submission of the September 12, 2024 Paragraph IV notice letter specifically addressing the patents-in-suit (Compl. ¶132, ¶303, ¶315). The prayer for relief seeks a judgment that the infringement has been willful and an enhancement of damages (Prayer for Relief ¶(g)).

VII. Analyst’s Conclusion: Key Questions for the Case

  • A core issue will be one of claim construction and technical comparison: Across a portfolio of sixteen patents covering intricate mechanical features, the case will likely devolve into a series of highly specific disputes over the meaning of key claim terms and whether the physical structures and operational parameters of Cipla's generic device, once revealed, fall within those construed terms.
  • A key evidentiary question will be one of method infringement: For the patents claiming methods of use (e.g., '643 and '953 patents concerning gas lock prevention), the central question will be whether the design of Cipla's device and the instructions in its proposed label will inevitably lead physicians to prescribe and patients to perform the claimed method steps.
  • A central dynamic of the case will be information disclosure: The complaint is necessarily pleaded on "information and belief." The case's development will be driven by the technical details contained in Cipla's confidential ANDA, turning the current general allegations into specific, evidence-based infringement and validity disputes that will define the contours of the litigation.